In a significant legal development, a settlement of $2.25 million has been reached with Teva Pharmaceuticals USA, Inc. and its parent company, Teva Pharmaceutical Industries Ltd., in relation to a class-action lawsuit concerning the anti-depressant Effexor XR and its generic versions. This legal action stems from allegations that Wyeth Pharmaceuticals, along with Teva, engaged in anticompetitive practices that effectively prevented the availability of generic versions of Effexor XR in the market. Plaintiffs contend that this behavior resulted in consumers and third-party payerssuch as health insurance companiespaying excessively high prices for both brand-name and generic forms of the medication.

It is important to note that both Teva and Wyeth deny any wrongdoing in this case. Additionally, a previous settlement involving Wyeth alone, valued at $25.5 million, was approved by the Court. This earlier settlement is separate from the current agreement and does not imply that Effexor XR is unsafe for consumption.

Who is Eligible for the Settlement?

This settlement includes individuals and entities that purchased, paid for, or reimbursed the costs of Effexor XR or its AB-rated generic counterparts between June 14, 2008, and May 31, 2011. The eligible participants must reside in specific states, which include Arizona, California, Florida, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nevada, New Hampshire, New Mexico, New York, North Carolina, Oregon, Rhode Island, South Dakota, Tennessee, West Virginia, and Wisconsin.

For a comprehensive overview of the criteria for inclusion in this settlement, interested parties can visit